151 related articles for article (PubMed ID: 38757347)
1. Application potential of senolytics in clinical treatment.
Li T; Li S; Ma K; Kong J
Biogerontology; 2024 Jun; 25(3):379-398. PubMed ID: 38109001
[TBL] [Abstract][Full Text] [Related]
2. Effects of senescence on the tumour microenvironment and response to therapy.
Reynolds LE; Maallin S; Haston S; Martinez-Barbera JP; Hodivala-Dilke KM; Pedrosa AR
FEBS J; 2024 Jun; 291(11):2306-2319. PubMed ID: 37873605
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.
Sun R; Wang J; Young KH
Crit Rev Oncog; 2017; 22(5-6):527-557. PubMed ID: 29604930
[TBL] [Abstract][Full Text] [Related]
4. Ageing microenvironment mediates lymphocyte carcinogenesis and lymphoma drug resistance: From mechanisms to clinical therapy (Review).
Zhang Y; Chu J; Hou Q; Qian S; Wang Z; Yang Q; Song W; Dong L; Shi Z; Gao Y; Meng M; Zhang M; Zhang X; Chen Q
Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757347
[TBL] [Abstract][Full Text] [Related]
5. Promoting whole person health: Exploring the role of traditional Chinese medicine in Polish healthcare.
Rybicka M; Zhao J; Piotrowicz K; Ptasnik S; Mitka K; Kocot-Kępska M; Hui KK
J Integr Med; 2023 Nov; 21(6):509-517. PubMed ID: 37925335
[TBL] [Abstract][Full Text] [Related]
6. Management of chronic myeloid leukemia in 2023 - common ground and common sense.
Senapati J; Sasaki K; Issa GC; Lipton JH; Radich JP; Jabbour E; Kantarjian HM
Blood Cancer J; 2023 Apr; 13(1):58. PubMed ID: 37088793
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia.
Yoshimura S; Panetta JC; Hu J; Li L; Gocho Y; Du G; Umezawa A; Karol SE; Pui CH; Mullighan CG; Konopleva M; Stock W; Teachey DT; Jain N; Yang JJ
Leukemia; 2023 Jun; 37(6):1194-1203. PubMed ID: 37076694
[TBL] [Abstract][Full Text] [Related]
8. Mitochondria as the Essence of Yang Qi in the Human Body.
Luo J; Shen S; Xia J; Wang J; Gu Z
Phenomics; 2022 Oct; 2(5):336-348. PubMed ID: 36939762
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas.
Shah SB; Carlson CR; Lai K; Zhong Z; Marsico G; Lee KM; Félix Vélez NE; Abeles EB; Allam M; Hu T; Walter LD; Martin KE; Gandhi K; Butler SD; Puri R; McCleary-Wheeler AL; Tam W; Elemento O; Takata K; Steidl C; Scott DW; Fontan L; Ueno H; Cosgrove BD; Inghirami G; García AJ; Coskun AF; Koff JL; Melnick A; Singh A
Nat Mater; 2023 Apr; 22(4):511-523. PubMed ID: 36928381
[TBL] [Abstract][Full Text] [Related]
10. Age-associated remodeling of T cell immunity and metabolism.
Han S; Georgiev P; Ringel AE; Sharpe AH; Haigis MC
Cell Metab; 2023 Jan; 35(1):36-55. PubMed ID: 36473467
[TBL] [Abstract][Full Text] [Related]
11. A bone-based 3D scaffold as an
Ceccato J; Piazza M; Pizzi M; Manni S; Piazza F; Caputo I; Cinetto F; Pisoni L; Trojan D; Scarpa R; Zambello R; Tos APD; Trentin L; Semenzato G; Vianello F
Front Oncol; 2022; 12():947823. PubMed ID: 36330473
[TBL] [Abstract][Full Text] [Related]
12. Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes.
Wang TW; Johmura Y; Suzuki N; Omori S; Migita T; Yamaguchi K; Hatakeyama S; Yamazaki S; Shimizu E; Imoto S; Furukawa Y; Yoshimura A; Nakanishi M
Nature; 2022 Nov; 611(7935):358-364. PubMed ID: 36323784
[TBL] [Abstract][Full Text] [Related]
13. The cross-talk between miRNAs and JAK/STAT pathway in cutaneous T cell lymphoma: Emphasis on therapeutic opportunities.
Patil K; Sher G; Kuttikrishnan S; Moton S; Alam M; Buddenkotte J; Ahmad A; Steinhoff M; Uddin S
Semin Cell Dev Biol; 2024 Feb; 154(Pt C):239-249. PubMed ID: 36216715
[TBL] [Abstract][Full Text] [Related]
14. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.
Alu A; Lei H; Han X; Wei Y; Wei X
J Hematol Oncol; 2022 Oct; 15(1):138. PubMed ID: 36183125
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO).
Gillessen S; Pluetschow A; Vucinic V; Ostermann H; Kobe C; Bröckelmann PJ; Böll B; Eichenauer DA; Heger JM; Borchmann S; Fuchs M; Borchmann P; Engert A; von Tresckow B
Eur J Haematol; 2022 Dec; 109(6):728-735. PubMed ID: 36056778
[TBL] [Abstract][Full Text] [Related]
16. The current state of the art and future trends in RAS-targeted cancer therapies.
Punekar SR; Velcheti V; Neel BG; Wong KK
Nat Rev Clin Oncol; 2022 Oct; 19(10):637-655. PubMed ID: 36028717
[TBL] [Abstract][Full Text] [Related]
17. Age-Associated B Cell Features of the Murine High-Grade B Cell Lymphoma Bc.DLFL1 and Its Extranodal Expansion in Abdominal Adipose Tissues.
Jia X; Bene J; Balázs N; Szabó K; Berta G; Herczeg R; Gyenesei A; Balogh P
J Immunol; 2022 Jun; 208(12):2866-2876. PubMed ID: 35867673
[TBL] [Abstract][Full Text] [Related]
18. Aging-associated and CD4 T-cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events.
Tsukamoto H; Komohara Y; Tomita Y; Miura Y; Motoshima T; Imamura K; Kimura T; Ikeda T; Fujiwara Y; Yano H; Kamba T; Sakagami T; Oshiumi H
Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2205378119. PubMed ID: 35858347
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
